Table 1.
Baseline demographics and clinical characteristics.
Fig 1.
Overall and progression free survival, treated metastasis control for all 361 oligometastatic patients treated with ablative radiotherapy.
Median survival was 47.1 months and 3-year survival was 56% (A). Median progression-free survival was 10.1 months and 3-year progression-free survival was 24% (B). Median treated metastasis control was not reached and 3-year TMC was 72% (C).
Table 2.
Univariate and multivariate analysis of overall survival (OS).
Table 3.
Univariate and multivariate analysis of progression-free survival (PFS).
Table 4.
Univariate and multivariate analysis of per patient treated metastasis control (TMC).
Fig 2.
Recursive partitioning models for overall survival and progression-free survival.
For overall survival, recursive partitioning allowed stratification of patients into five prognostic classes (A). Overall survival was well-stratified based on RPA class (B); log-rank p < 0.01. For progression-free survival, recursive partitioning allowed stratification of patients into two prognostic classes (C). Progression-free survival was well-stratified based on RPA class (D); log-rank p < 0.01.
Fig 3.
Overall and progression free survival, treated metastasis control by minimum biologically effective dose (BED).
BED ≥75 Gy was associated with greater overall survival (p < 0.01) (A) and treated metastasis control (p < 0.01) (C), with trend for progression free survival (p = 0.06) (B).